Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies

• Main Authors: Arif Hussain, Anwarul Hasan, Mohammad Mahdi Nejadi Babadaei, Samir Haj Bloukh, Muhammad E.H. Chowdhury, Majid Sharifi, Setareh Haghighat, Mojtaba Falahati
• Format: Article
• Language: English
• Published: Elsevier 2020-10-01
• Series: Biomedicine & Pharmacotherapy
• Subjects: Corona virus; spike protein; receptor binding domain; antibodies; epitope-specific vaccines (ESV)
• Online Access: http://www.sciencedirect.com/science/article/pii/S0753332220307526

As the number of people infected with the newly identified 2019 novel coronavirus (SARS-CoV2) is continuously increasing every day, development of potential therapeutic platforms is vital. Based on the comparatively high similarity of receptor-binding domain (RBD) in SARS-CoV2 and SARS-CoV, it seems crucial to assay the cross-reactivity of anti-SARS-CoV monoclonal antibodies (mAbs) with SARS-CoV2 spike (S)-protein. Indeed, developing mAbs targeting SARS-CoV2 S-protein RBD could show novel applications for rapid and sensitive development of potential epitope-specific vaccines (ESV). Herein, we present an overview on the discovery of new CoV followed by some explanation on the SARS-CoV2 S-protein RBD site. Furthermore, we surveyed the novel therapeutic mAbs for targeting S-protein RBD such as S230, 80R, F26G18, F26G19, CR3014, CR3022, M396, and S230.15. Afterwards, the mechanism of interaction of RBD and different mAbs were explained and it was suggested that one of the SARS-CoV-specific human mAbs, namely CR3022, could show the highest binding affinity with SARS-CoV2 S-protein RBD. Finally, some ongoing challenges and future prospects for rapid and sensitive advancement of therapeutic mAbs targeting S-protein RBD were discussed. In conclusion, it may be proposed that this review may pave the way for recognition of RBD and different mAbs to develop potential therapeutic ESV.